Yosu Luque

In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice

Kristen Browder, Pradeep Reddy, Mako Yamamoto et al. · Nature Aging · 2022 · 217 citations

Developmental Biology, Aging, Longevity +8

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 203 citations · Full text

Vancomycin-Associated Cast Nephropathy

Yosu Luque, Kévin Louis, Chantal Jouanneau et al. · Journal of the American Society of Nephrology · 2017 · 149 citations · Full text

Administration of Recombinant Soluble Urokinase Receptor Per Se Is Not Sufficient to Induce Podocyte Alterations and Proteinuria in Mice

Dominique Cathelin, Sandrine Placier, Michael Ploug et al. · Journal of the American Society of Nephrology · 2014 · 72 citations · Full text

Podocyte Alterations, Renal Pathology, Immunology +17

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Thomas Barbour, Marie Scully, Gema Ariceta et al. · Kidney International Reports · 2021 · 63 citations · Full text